noscript

News and Announcements

OncoSil Receives $2.3m R&D Tax Incentive Refund

  • Published September 27, 2016 3:05PM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

26th September 2016, ASX Announcement

OncoSil Medical Limited (ASX:OSL) (OncoSil Medical or the Company) a late stage medical company focused on localised treatments for subjects with pancreatic and liver cancer, is pleased to announce it has received a cash refund from the Australian Taxation Office of $2.3 million following the lodgement of the 2015/16 financial year tax return. The cash is rebate is related to the expenditure on eligible Australian and international R&D activities conducted during the 2015/16 financial year.

The Company has approximately $14.0m in cash and cash equivalents with the receipt of these funds.

To view the full announcement, please click on the button below.

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now